FORTY SEVEN, INC.

FTSV NASDAQ
10.12
0.00
0.00%
After Hours: 9.84 -0.28 -2.77% 17:08 07/16 EDT
Open
10.13
Prev Close
10.12
High
10.26
Low
10.03
Volume
118.40K
Avg Vol (3M)
228.82K
52 Week High
23.83
52 Week Low
9.76
% Turnover
0.40%
Market Cap
299.81M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers FORTY SEVEN, INC. FTSV stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Forty Seven, Inc. is clinical-stage immuno-oncology company. The Company is focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The Company’s lead product candidate, 5F9, is a humanized IgG4 subclass monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPa receptor on macrophages. The Company’s another product FSI-189, is an antibody that binds to SIRPa and initiate Phase I solid tumor trials for FSI-189. The Company is investigating 5F9 in multiple Phase I and Phase II trials in various cancers including acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL) and colorectal carcinoma (CRC), and ovarian cancer, as both a monotherapy and in combination with other therapies, such as rituximab and cetuximab. In addition to the 5F9, which is an antibody that binds to CD47 blocking its binding to SIRPa.
MORE >

Recently

Name
Price
%Change